Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Achieve Life Sciences Inc Market Cap
Based on ratings from 1 stock analysts, the Achieve Life Sciences Inc stock price is expected to increase by 223.23% in 12 months. This is calculated by using the average 12-month stock price forecast for Achieve Life Sciences Inc. The lowest target is $10 and the highest is $30. Please note analyst price targets are not guaranteed and could be missed completely.
ACHV is a stock in Healthcare which has been forecasted to be worth $16 as an average. On the higher end, the forecast price is $30 USD by from and on the lower end ACHV is forecasted to be $10 by from .
These are the latest 20 analyst ratings of ACHV.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Gary Nachman Raymond James | Strong Buy | $20 | Initiates | Sep 27, 2024 |
| Francois Brisebois Oppenheimer | Outperform | $11 | Reiterates | Aug 15, 2024 |
| Francois Brisebois Oppenheimer | Outperform | $11 | Maintains | May 13, 2024 |
| Justin Walsh JonesTrading | Buy | $20 | Initiates | Apr 17, 2024 |
| Francois Brisebois Oppenheimer | Outperform | $18 | Reiterates | Apr 1, 2024 |
| Thomas Flaten Lake Street | Buy | $11 | Maintains | Mar 5, 2024 |
| Francois Brisebois Oppenheimer | Outperform | $18 | Maintains | Dec 12, 2023 |
Lake Street | Buy | Maintains | Jun 1, 2023 | |
| Thomas Flaten Lake Street | Buy | $19 | Maintains | May 31, 2023 |
| Thomas Flaten Lake Street | Buy | $22 | Maintains | May 10, 2023 |
| Francois Brisebois Oppenheimer | Outperform | $17 | Reiterates | Mar 17, 2023 |
| Jason McCarthy Maxim Group | Buy | $8 | Maintains | Nov 16, 2022 |
| James Molloy Alliance Global Partners | Buy | $25 | Initiates | Oct 4, 2021 |
Oppenheimer | Outperform | Initiates | Jun 23, 2021 | |
H.C. Wainwright | Buy | Initiates | Nov 25, 2020 | |
Maxim Group | Buy | Initiates | Nov 25, 2020 | |
Lake Street | Buy | Initiates | Nov 25, 2020 | |
Lake Street | Buy | Initiates | Sep 17, 2020 | |
H.C. Wainwright | Buy | Initiates | Feb 25, 2020 | |
HC Wainwright & Co. | Buy | Initiates | Feb 25, 2020 |
When did it IPO
1995
Staff Count
22
Country
Canada
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Richard A. B. Stewart
Market Cap
$178.6M
In 2023, ACHV generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that ACHV's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 01 Oct 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Achieve Life Sciences has appointed Dr. Mark L. Rubinstein as Head of Medical Affairs, enhancing its focus on cytisinicline for smoking cessation. Dr. Rubinstein has over 20 years of relevant experience.
Why It Matters - The appointment of Dr. Rubinstein enhances Achieve Life Sciences' leadership in smoking cessation, potentially boosting investor confidence and impacting stock performance due to his expertise.
Mon, 26 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Achieve Life Sciences announced Richard Stewart will return as CEO, while Thomas King has been appointed Executive Chairman of the Board, effective August 26, 2024.
Why It Matters - Leadership changes can impact company strategy and performance. Stewart’s return as CEO may signal a shift in direction for Achieve Life Sciences, influencing investor confidence and stock performance.
Wed, 14 Aug 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Achieve Life Sciences (NASDAQ: ACHV) will hold its Q2 2024 Earnings Conference Call on August 13, 2024, at 4:30 PM ET, featuring key company executives and analysts.
Why It Matters - Achieve Life Sciences' earnings call provides insights into financial performance and strategic direction, influencing stock valuation and investor sentiment.
Tue, 13 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - The company will host a conference call today, August 13, 2024, at 4:30 PM EDT. Investors may want to tune in for updates and information.
Why It Matters - The conference call may provide insights into company performance, future guidance, and strategic plans, potentially impacting stock prices and investment decisions.
Wed, 31 Jul 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Cytisinicline received designation based on Phase 2 ORCA-V1 trial results, which showed it more than doubled the odds of quitting e-cigarettes versus placebo.
Why It Matters - The successful Phase 2 trial for cytisinicline enhances its market potential, potentially boosting sales and stock prices for companies involved in smoking cessation products.
Mon, 29 Jul 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Achieve Life Sciences has secured a $20 million debt refinancing agreement with Silicon Valley Bank, extending the maturity date from August 1, 2024, to December 1, 2027.
Why It Matters - Achieve Life Sciences' $20 million debt refinancing extends maturity, improving cash flow stability and reducing immediate repayment pressure, which may enhance investor confidence in its growth prospects.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
